The Clone-Censor-Weight Method in Pharmacoepidemiologic Research: Foundations and Methodological Implementation

No abstract is available for this paper.

• Publication year

  2024

• Venue

  Current Epidemiology Reports

• Publication date

  2024-02-17

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s40471-024-00346-2
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Emulating a Target Trial Using Observational Data.

  2025cited by this paper
• Comparative Effectiveness of Dynamic Treatment Strategies for Medication Use and Dosage: Emulating a Target Trial Using Observational Data

  2023cited by this paper
• Inverse probability weighting to estimate exposure effects on the burden of recurrent outcomes in the presence of competing events.

  2023cited by this paper
• Impact of beta-blockers on mortality and cardiovascular disease outcomes in patients with obstructive sleep apnoea: a population-based cohort study in target trial emulation framework

  2023cited by this paper
• Effect of selective serotonin reuptake inhibitor treatment following diagnosis of depression on suicidal behaviour risk: a target trial emulation

  2023cited by this paper
• Target Trial Emulation to Improve Causal Inference from Observational Data: What, Why, and How?

  2023cited by this paper
• Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance

  2023cited by this paper
• Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records

  2023cited by this paper
• Eliminating Ambiguous Treatment Effects Using Estimands

  2023cited by this paper
• Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis

  2023cited by this paper
• The effect of duration of therapy for treatment of Staphylococcus aureus blood stream infection: an application of cloning to deal with immortal-time bias in an analysis of data from a cohort study (BSI-FOO)

  2022cited by this paper
• No Short-Term Mortality from Benzodiazepine Use Post-Acute Ischemic Stroke After Accounting for Bias.

  2022cited by this paper
• Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data.

  2022cited by this paper
• Target Trial Emulation: A Framework for Causal Inference From Observational Data.

  2022cited by this paper
• Causal analyses with target trial emulation for real-world evidence removed large self-inflicted biases: Systematic bias assessment of ovarian cancer treatment effectiveness.

  2022cited by this paper
• HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real‐world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force

  2022cited by this paper
• Trimodality Therapy vs Definitive Chemoradiation in Older Adults With Locally Advanced Esophageal Cancer

  2022cited by this paper
• The effect of myomectomy on reproductive outcomes in patients with uterine fibroids: A retrospective cohort study.

  2022cited by this paper
• The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example

  2022cited by this paper
• Timing of adjuvant chemotherapy initiation and mortality among colon cancer patients at a safety-net health system

  2022cited by this paper
• On the logic of collapsibility for causal effect measures

  2021cited by this paper
• STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies

  2021cited by this paper
• What Is Your Estimand? Defining the Target Quantity Connects Statistical Evidence to Theory

  2021cited by this paper
• Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease: nationwide cohort study

  2021cited by this paper
• Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes.

  2021cited by this paper
• Causal survival analysis: A guide to estimating intention-to-treat and per-protocol effects from randomized clinical trials with non-adherence

  2021cited by this paper
• Practical demonstration of time bias with administration of adjuvant therapy in lung cancer.

  2021cited by this paper
• Association of a Shortened Duration of Adjuvant Chemotherapy With Overall Survival Among Individuals With Stage III Colon Cancer

  2021cited by this paper
• Understanding and identifying immortal-time bias in surgical health services research: An example using surgical resection of stage IV breast cancer.

  2021cited by this paper
• Emulation of a Target Trial to Evaluate the Causal Effect of Palliative Care Consultation on the Survival Time of Patients with Hepatocellular Carcinoma

  2021cited by this paper
• Emulating a target trial of statin use and risk of dementia using cohort data

  2020cited by this paper
• Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens

  2020cited by this paper
• Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data

  2020cited by this paper
• Adjusting for adherence in randomized trials when adherence is measured as a continuous variable: An application to the Lipid Research Clinics Coronary Primary Prevention Trial

  2020cited by this paper
• Immortal Time Bias in Epidemiology

  2019cited by this paper
• Improved adherence adjustment in the Coronary Drug Project

  2018cited by this paper
• An unjustified benefit: immortal time bias in the analysis of time‐dependent events

  2018cited by this paper
• Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer

  2018cited by this paper
• Patients and investigators prefer measures of absolute risk in subgroups for pragmatic randomized trials.

  2018cited by this paper
• How to estimate the effect of treatment duration on survival outcomes using observational data

  2018cited by this paper
• When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study

  2016cited by this paper
• Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available.

  2016cited by this paper
• Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses.

  2016cited by this paper
• Immortal time bias in observational studies of time-to-event outcomes.

  2016cited by this paper
• Effectiveness of Screening Colonoscopy to Prevent Colorectal Cancer Among Medicare Beneficiaries Aged 70 to 79 Years

  2016cited by this paper
• Pharmacovigilance

  2015cited by this paper
• Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.

  2015cited by this paper
• Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research

  2015cited by this paper
• Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study.

  2015cited by this paper
• Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.

  2014cited by this paper
• Metformin and the Risk of Cancer

  2012cited by this paper
• When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries

  2011cited by this paper
• Landmark Analysis at the 25-Year Landmark Point

  2011cited by this paper
• The hazards of hazard ratios.

  2010cited by this paper
• Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals.

  2009cited by this paper
• Immortal time bias in critical care research: Application of time-varying Cox regression for observational cohort studies*

  2009cited by this paper
• Immortal time bias in pharmaco-epidemiology.

  2008cited by this paper
• Survival analysis: time-dependent effects and time-varying risk factors.

  2008cited by this paper
• Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods.

  2005cited by this paper
• Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies.

  2003influential reference
• Analysis of survival by tumor response.

  1983cited by this paper
• Practice of Epidemiology Estimating the Burden of Recurrent Events in the Presence of Competing Risks: the Method of Mean Cumulative Count

  year unknowncited by this paper

• Identifying and avoiding design related biases in observational studies using the target trial framework.

  2026cites this paper
• Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients With Gout.

  2026cites this paper
• Causal Multistate Models to Evaluate Treatment Delay

  2025cites this paper
• Target trial emulation framework: mitigating methodological challenges and application in COVID-19 treatment evaluation studies.

  2025cites this paper
• Comparative Effectiveness of Long-Acting Lipoglycopeptides vs Standard-of-Care Antibiotics in Serious Bacterial Infections

  2025cites this paper
• CTRH as Biomarker of Drug Efficacy: In-Depth Assessment of Real-World Evidence.

  2025cites this paper
• Early use of albumin may increase the risk of sepsis-associated acute kidney injury in sepsis patients: a target trial emulation

  2025cites this paper
• Fecal immunochemical test surveillance in colorectal cancer following adenoma resection: A longitudinal, population-based linked cohort study in China

  2025cites this paper
• Target trial emulation of statin discontinuation in multimorbid older adults with polypharmacy

  2025cites this paper
• Impact of digoxin versus beta-blocker in patients with coexistent atrial fibrillation and heart failure: a target trial emulation

  2025cites this paper
• Survival Benefits of Deceased Donor Kidney Transplant vs Waitlisting.

  2025cites this paper
• The Reporting and Methodological Recommendations for Observational Studies Estimating the Effects of Deprescribing Medications (REMROSE‐D) ISPE‐Endorsed Guidance

  2025cites this paper
• Requiring continuous enrollment during follow-up? A call for robust research methods.

  2025cites this paper
• Application of the Target Trial Emulation Framework to Studies in the Pediatric Population.

  2025cites this paper
• Demystifying Clone‐Censor‐Weighting to Studying Treatment Initiation Windows: An Example Using Publicly Available Synthetic Medicare Claims Data

  2025cites this paper
• Effectiveness of Adalimumab Biosimilars and Originator for Psoriasis.

  2025cites this paper
• Exploring the Application of Target Trial Emulation in Vaccine Evaluation: Scoping Review and Recommendations for Future Studies

  2024cites this paper
• "Target Trial Emulation" for Observational Studies - Potential and Pitfalls.

  2024cites this paper